Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 19, 2018 06:35 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
March 01, 2018 16:20 ET | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
January 29, 2018 09:00 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the human gut...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
November 29, 2017 09:30 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
November 02, 2017 16:52 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
September 29, 2017 08:00 ET | Ritter Pharmaceuticals
Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
red.jpg
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
August 17, 2017 07:00 ET | RedHill Biopharma Ltd.
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories          Esomeprazole Strontium DR...
red.jpg
RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017
July 18, 2017 07:00 ET | RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
red.jpg
Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting
March 02, 2015 07:00 ET | RedHill Biopharma Ltd.
The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...